Prostate cancer is the most common urological malignancy and the leading cause of cancer death in men worldwide. It is a heterogeneous disease with wide variability. Genomic markers, combined with clinical and pathological variables, are useful tools for reducing unnecessary biopsies, stratifying low-risk tumors from high-risk tumors, and guiding personalized treatment decisions. Variants of the TEP1 gene are of great interest as a genetic marker of the risk of developing prostate malignancies.

Keywords: single-nucleotide polymorphisms, TEP 1, biochemical relapse, telomeres, telomerase, prostate cancer